Biogen Inc. and Stoke Therapeutics Inc. shared new data on zorevunersen as a treatment for Dravet syndrome, showing sustained improvements in patients over two years. Results from three-year studies indicated that 95% of patients experienced overall clinical status improvements. Safety and tolerability remained key endpoints, with patients demonstrating reduced seizure frequency and improved cognitive and behavioral measures. The Phase 3 EMPEROR study is currently evaluating a dosing regimen of zorevunersen. Stoke Therapeutics’ stock closed at $29.90 on Thursday. More health news can be found on rttnews.com.

Read more at Nasdaq, Inc.: Biogen And Stoke Therapeutics Present Promising Long-Term Data For Zorevunersen In Dravet Syndrome